Takako Araki

About

Dr. Takako Araki is an Associate Professor in the Division of Endocrinology, Diabetes and Metabolism at the University of Minnesota. Her professional focus is dedicated to the quality improvement of pituitary perioperative patient care and the study of various pituitary disorders. Dr. Araki leads the Araki Lab, which conducts research related to pituitary function and dysfunction, including investigations into post-COVID pituitary dysfunction. Her work aims to enhance clinical outcomes and deepen understanding of pituitary disease mechanisms through both clinical and laboratory research approaches.

Research topics

• Medicine
• Internal medicine
• Endocrinology
• Biology
• Surgery
• Genetics
• Oncology
• Pediatrics
• Immunology
• Bioinformatics

Selected publications

• Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial

  The Journal of Clinical Endocrinology & Metabolism · 2020 · 48 citations

  CONTEXT: Combination therapy with somatostatin receptor ligand (SRL) plus pegvisomant for patients with acromegaly is recommended after a maximizing dose on monotherapy. Lower-dose combination regimens are not well studied. OBJECTIVE: To compare cost-effectiveness and efficacy of 3 lower-dose combination regimens in controlled and uncontrolled acromegaly. DESIGN AND SETTING: Prospective, randomized, open-label, parallel arm study at a tertiary referral pituitary center. PATIENTS: Adults with acr…

  PublisherOA PDFDOI

• Two Distinctive <i>POMC</i> Promoters Modify Gene Expression in Cushing Disease

  The Journal of Clinical Endocrinology & Metabolism · 2021 · 33 citations

  1st authorCorresponding

  CONTEXT: Mechanisms underlying pituitary corticotroph adenoma adrenocorticotropin (ACTH) production are poorly understood, yet circulating ACTH levels closely correlate with adenoma phenotype and clinical outcomes. OBJECTIVE: We characterized the 5' ends of proopiomelanocortin (POMC) gene transcripts, which encode the precursor polypeptide for ACTH, in order to investigate additional regulatory mechanisms of POMC gene transcription and ACTH production. METHODS: We examined 11 normal human pituit…

  PublisherOA PDFDOI

• Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors

  Frontiers in Endocrinology · 2021 · 29 citations

  Senior authorCorresponding

  Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide r…

  PublisherOA PDFDOI

• A Case of Hypophysitis Associated With SARS-CoV-2 Vaccination

  AACE Clinical Case Reports · 2022 · 27 citations

  Senior authorCorresponding

  Background/Objective: Although SARS-CoV-2 vaccines have been developed with multiple novel technologies and rapidly disseminated worldwide, the full profile of adverse effects has not been known. Recently, there are sporadic but increasing reports of endocrinopathy in relation to SARS-CoV-2 vaccination. Here we report a rare case of hypophysitis with acute onset of diabetes insipidus, immediately after SARS-CoV-2 vaccination. Case Report: A 48-year-old female patient had been in her usual state…

  PublisherOA PDFDOI

• Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing’s Disease

  Endocrinology · 2022-06-09 · 10 citations

  articleOpen access1st authorCorresponding

  Nonsurgical medical treatments are often performed for Cushing's disease due to high recurrence rates. However, current medical treatment that targets corticotroph adenomas are limited. To develop a treatment that specifically targets corticotrophs in Cushing's disease, it is necessary to identify corticotroph lineage-specific proteins, which are involved in the Cushing's tumor phenotype. We have previously reported that the expression of E2F transcription factor 1 (E2F1), one of the cell cycle…

  PublisherOA PDFDOI

Recent grants

• Mechanisms for post-COVID pituitary damage

  NIH · $1.2M · 2021–2025

Frequent coauthors

• Leonid Poretsky

  Lenox Hill Hospital

  14 shared

• Paul B. Moore

  13 shared

• Шломо Мелмед

  Cedars-Sinai Medical Center

  10 shared

• Donna Seto‐Young

  Mount Sinai Beth Israel

  9 shared

• Yasuhiko Kawakami

  University of Minnesota

  8 shared

• Paul B. Moore

  RTI International

  8 shared

• Hidenori Fukuoka

  Kobe University Hospital

  7 shared

• Ramachandra P. Tummala

  7 shared

Labs

• Araki LabPI

Awards & honors

• Clinical Excellence, University of Minnesota, 2023, 2024, 20…
• North American Skull Base Society Research Award 2022
• Minnesota Monthly "Top Doctors", 2022

Similar researchers at University of Minnesota

• Emmanuel Antonarakish-99
• Elizabeth Seaquisth-53
• Mahsa Abassih-34